MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

Impact · against what's priced in

The BARDA contract provides Vericel and MediWound with significant long-term revenue visibility and a path toward market expansion into blast trauma injuries. This is a material positive catalyst as it guarantees baseline cash flow and validates the strategic importance of NexoBrid for the U.S. Strategic National Stockpile.

VCEL+0.70

No priced-in read yet